The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Background The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …

Background High-dose chemotherapy plus autologous stem-cell transplantation has been
the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of …

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or …

Autologous hematopoietic stem cell transplantation (ASCT) improves survival in multiple
myeloma (MM). However, many individuals are unable to collect optimal CD34+ …

Relapsed and refractory (R/R) multiple myeloma (MM) patients have very poor prognosis.
Chimeric antigen receptor modified T (CAR T) cells is an emerging approach in treating …

B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-
cell therapy in multiple myeloma (MM). Despite promising objective response rates, most …

Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable.
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T …